Since TP73 is rarely mutated in cancers, one of the latest promising strategies in targeting mutant p53 cancers, apart from reactivating mutant p53 itself, is represented by the reactivation of other p53 family members, including p73 [61]. This evidence concerns the gene TP53 and cancer.